Key Points
- James Hamilton sold 10,000 shares of Arrowhead Pharmaceuticals on April 23 at an average price of $75, totaling $750,000, reducing his holding to 226,958 shares (a 4.22% decrease) under a pre-arranged Rule 10b5-1 plan.
- Arrowhead's most recent quarter showed revenue of $264.03 million (up 10,461.3% year-over-year) but an EPS miss of $0.22 versus a $0.60 consensus.
- Analyst sentiment is broadly positive with a consensus Moderate Buy and an average price target of $83.78; the stock trades near its 52-week high ($76.76) and has a market cap of about $10.35 billion.
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Get Free Report) insider James Hamilton sold 10,000 shares of the stock in a transaction on Thursday, April 23rd. The shares were sold at an average price of $75.00, for a total transaction of $750,000.00. Following the transaction, the insider directly owned 226,958 shares in the company, valued at approximately $17,021,850. This represents a 4.22% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Arrowhead Pharmaceuticals Price Performance
ARWR stock opened at $73.91 on Friday. The company has a debt-to-equity ratio of 0.29, a quick ratio of 3.38 and a current ratio of 3.38. Arrowhead Pharmaceuticals, Inc. has a 52 week low of $12.44 and a 52 week high of $76.76. The firm's fifty day moving average is $62.83 and its 200 day moving average is $58.21. The firm has a market cap of $10.35 billion, a P/E ratio of 48.31 and a beta of 1.26.
Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last released its earnings results on Thursday, February 5th. The biotechnology company reported $0.22 EPS for the quarter, missing the consensus estimate of $0.60 by ($0.38). Arrowhead Pharmaceuticals had a net margin of 18.54% and a return on equity of 35.64%. The business had revenue of $264.03 million for the quarter, compared to the consensus estimate of $225.66 million. During the same period in the prior year, the business posted ($1.39) EPS. Arrowhead Pharmaceuticals's revenue for the quarter was up 10461.3% on a year-over-year basis. Research analysts predict that Arrowhead Pharmaceuticals, Inc. will post -3.37 earnings per share for the current year.
Wall Street Analysts Forecast Growth
ARWR has been the topic of several recent research reports. The Goldman Sachs Group increased their target price on shares of Arrowhead Pharmaceuticals from $50.00 to $85.00 and gave the company a "neutral" rating in a report on Wednesday, January 7th. Weiss Ratings raised shares of Arrowhead Pharmaceuticals from a "sell (d-)" rating to a "hold (c-)" rating in a report on Friday, February 6th. HC Wainwright reaffirmed a "buy" rating and set a $100.00 target price on shares of Arrowhead Pharmaceuticals in a report on Wednesday, March 25th. Chardan Capital increased their target price on shares of Arrowhead Pharmaceuticals from $60.00 to $80.00 and gave the company a "buy" rating in a report on Wednesday, January 7th. Finally, Morgan Stanley raised shares of Arrowhead Pharmaceuticals from an "equal weight" rating to an "overweight" rating and raised their price target for the stock from $78.00 to $100.00 in a report on Tuesday. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $83.78.
View Our Latest Analysis on Arrowhead Pharmaceuticals
Institutional Investors Weigh In On Arrowhead Pharmaceuticals
Large investors have recently added to or reduced their stakes in the company. Tsfg LLC bought a new stake in Arrowhead Pharmaceuticals in the 4th quarter worth $25,000. First Horizon Corp bought a new stake in Arrowhead Pharmaceuticals in the 4th quarter worth $32,000. WPG Advisers LLC grew its holdings in Arrowhead Pharmaceuticals by 384.8% in the 4th quarter. WPG Advisers LLC now owns 543 shares of the biotechnology company's stock worth $36,000 after acquiring an additional 431 shares during the last quarter. Hantz Financial Services Inc. grew its holdings in Arrowhead Pharmaceuticals by 177.1% in the 4th quarter. Hantz Financial Services Inc. now owns 737 shares of the biotechnology company's stock worth $49,000 after acquiring an additional 471 shares during the last quarter. Finally, Elyxium Wealth LLC bought a new stake in Arrowhead Pharmaceuticals in the 4th quarter worth $54,000. Institutional investors own 62.61% of the company's stock.
Arrowhead Pharmaceuticals Company Profile
(
Get Free Report)
Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company's approach aims to offer durable, targeted treatments across a range of therapeutic areas.
The company's pipeline includes multiple candidates in various stages of development.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
